Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
Patents for C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
11/2005
11/17/2005WO2005065266A8 Di-substituted pyrrolotriazine compounds
11/17/2005WO2005051954A3 PROCESSES FOR THE PREPARATION OF PYRAZOLO[1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF
11/17/2005WO2005051906A3 Heterocyclic inhibitors of mek and methods of use thereof
11/17/2005US20050256310 Therapeutic compounds
11/17/2005US20050256309 Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
11/17/2005US20050256282 Process for producing contact product; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256139 Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
11/17/2005US20050256138 Reacting a 5-aminotriazole with phenylmalonates to form dihydroxytriazolpyrimidines, halogenating the intermediate to form a dihalogen compound, reacting dihalogen derivative with an amine compound to form 5-halo-7-aminotriazolopyrimidines
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256125 Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example; use with other antitumor agents
11/17/2005US20050256124 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
11/17/2005US20050256109 HIV integrase inhibitors: cyclic pyrimidinone compounds
11/17/2005US20050256106 Such as 1-phenylsulfonyl-4-piperazinylindole hydrochloride for treatment or prophylaxis of disease mediated by serotonin related receptor, obesity, and/or central nervous system disorder
11/17/2005US20050256102 Inhibit Aurora kinase; cancer; 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-methylamino-ethyl)-benzamide; 9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine
11/17/2005US20050256101 Plant extracts and alkaloids having antitussive activity
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050255475 Energy transfer dyes, terminators and use thereof
11/17/2005US20050255391 Polymerisable diketopyrrolopyrroles, use of such compounds in colour filters and polymers prepared from these compounds
11/17/2005US20050255065 Aluminium and hexamethylenetetramine complex and the applications thereof
11/17/2005US20050255040 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
11/17/2005CA2565695A1 Certain chemical entities and compositions for use in the treatment of a cellular proliferative disease or disorder
11/16/2005EP1595143A1 The detection and identification of saxiphilins using saxitoxin-biotin conjugates
11/16/2005EP1594882A1 Process for preparing branched ribonucleosides from 1, 2-anhydroribofuranose intermediates
11/16/2005EP1594876A1 Conducting polymers with porphyrin cross-linkers
11/16/2005EP1594875A1 Porphyrin derivatives
11/16/2005EP1594873A1 Pyrrolidinohydrochinazolines
11/16/2005EP1594872A1 Cannabinoid receptor ligands and uses thereof
11/16/2005EP1594869A2 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
11/16/2005EP1594848A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
11/16/2005EP1594506A1 Benzo (1,2,5) thiadiazole als crf-antagonisten
11/16/2005EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors
11/16/2005EP1370557B1 Benzimidazole anti-inflammatory compounds
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
11/16/2005EP1317442B1 Quinolinone derivatives as tyrosine kinase inhibitors
11/16/2005EP1222191B1 Benzodiazepin derivatives, the production and use thereof
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/16/2005EP1114052B1 4-aminopyrrolopyrimidines as kinase inhibitors
11/16/2005EP1021712B1 Phosphorescent dendritic macromolecular compounds for imaging tissue oxygen
11/16/2005EP0981517B1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides
11/16/2005CN1696162A Process for producing contact product, catalyst component for addition polymerization, process for producing catalyst for addition polymerization, and process for producing addition polymer
11/16/2005CN1696130A Method for continuous extracting chlorophyll from silkworm dropping
11/16/2005CN1227253C Method for producing sulfonamide-substituted imidazotriazinones
11/16/2005CN1227250C Process for preparing azacycloalkanoyl aminothiazoles
11/15/2005US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
11/15/2005US6964977 E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964964 Anticancer agents
11/15/2005US6964960 Indoloquinazolinones
11/15/2005US6964957 For use in therapy of neurodegenerative diseases and certain cancers
11/15/2005US6964844 Water solubility; competitive binding immunoassay; qualitative or quantitative analysis
11/15/2005CA2248802C Meso-substituted tripyrrane compounds, compositions, and methods for making and using the same
11/15/2005CA2164847C O6-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells
11/10/2005WO2005105820A2 Macrocyclic cadmium complexes
11/10/2005WO2005105814A1 Tetracyclic inhibitors of janus kinases
11/10/2005WO2005105806A1 Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
11/10/2005WO2005105805A1 Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production thereof
11/10/2005WO2005105804A1 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT
11/10/2005WO2005105788A1 Indole derivatives and use thereof as kinase inhibitors
11/10/2005WO2005105760A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005WO2005105082A1 Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
11/10/2005WO2005097797A3 Compounds with atypical antipsychotic activity
11/10/2005WO2005082849A8 Lactams as conformationally constrained peptidomimetic inhibitors
11/10/2005US20050250957 Compounds containing thiosulfate moieties
11/10/2005US20050250836 Inhibitors of checkpoint kinases (Wee1 and Chk1)
11/10/2005US20050250834 11-(Aminoalkyl)isoindolo[2,1-a]indol-6-ones: 11-(2-Dimethylaminoethyl)-2-fluoroisoindolo[2,1-a]indol-6-one; psychological disorders, drug abuse, sleep disorders, Alzheimer's, Parkinson's and Huntington's disease, Irritable bowel syndrome, chemotherapy induced emesis, spinal trauma and/or head injury
11/10/2005US20050250830 Substituted amine radical as building blocks; increases structural diversity
11/10/2005US20050250829 Kinase inhibitors
11/10/2005US20050250823 Gyrase inhibitors
11/10/2005US20050250810 Screening for an enzyme inhibitor of Fab I or Fab K using providing a reaction mixture comprising Fab I or Fab K, crotonyl-ACP and NAPDH or NADH; contacting a candidate compound with the reaction mixture; and detecting inhibition of Fab I or Fab K; bactericides; fungicides; antibiotics; Stapylococcus
11/10/2005US20050250798 E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke
11/10/2005US20050250793 Preventives/remedies for hot flash
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250782 Heterocyclic inhibitors of MEK and methods of use thereof
11/10/2005US20050250780 Piperimido[1,2-a]piperazine-4,7diones derivatives; neurokinin (tachykinin) receptor antagonists; mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins; analgesic, neurodegenerative disorders, respiratory diseases, antiinflammatory agent, antidepressant
11/10/2005US20050250777 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications
11/10/2005US20050250765 Diazepinones as antiviral agents
11/10/2005US20050250763 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/10/2005US20050250760 1-[(Indol-3-yl)carbonyl]piperazine derivatives
11/10/2005US20050250741 non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive
11/10/2005DE102004019276A1 New cyanopyrrolizine derivatives, used e.g. for lowering blood sugar, treating type 2 diabetes, treating disorders of lipid and carbohydrate metabolism, treating arteriosclerotic symptoms
11/10/2005CA2564277A1 7h-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
11/10/2005CA2564085A1 Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
11/10/2005CA2562177A1 Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
11/09/2005EP1593682A2 Derivatives of 4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides, process for their preparation and pharmaceutical compositions thereof
11/09/2005EP1592693A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists
11/09/2005EP1592691A1 Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands
11/09/2005EP1592686A1 Gyrase inhibitors and uses thereof
11/09/2005EP1592684A1 Malonamide derivatives as gamma-secretase inhibitors
11/09/2005EP1592670A1 Mercaptoimidazoles as ccr2 receptor antagonists
11/09/2005EP1592426A1 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
11/09/2005EP1480983B1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
11/09/2005EP1480981B1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
11/09/2005EP1472258B1 Method for the synthesis of porphyrins and calix(4)pyrroles
11/09/2005EP1463732A4 Hydroxycucurbituril derivatives, their preparation methods and uses
11/09/2005EP1390369B1 4-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives
11/09/2005EP1377585B1 Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
11/09/2005CN1694886A Novel imidazopyrazines as cyclin dependent kinase inhibitors
11/09/2005CN1694871A Imidazolopyridines and methods of making and using the same
1 ... 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 ... 573